MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: Minireview

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted therapies for non-small cell lung cancer (NSCLC) have shown promise but are often limited by drug resistance.
• Driver oncogene alterations (e.g., EGFR, ALK, MET, RAS) are crucial in NSCLC pathogenesis.
• MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in cancer development and drug resistance.

Purpose of the Study:

• To explore how specific miRNAs regulate oncogenic driver pathways in NSCLC.
• To highlight the involvement of miRNAs in resistance mechanisms against targeted therapies.
• To discuss the potential of using small-interfering RNAs (siRNAs) or artificial miRNAs as novel anti-cancer treatments.

Main Methods:

• Literature review of studies investigating miRNA function in NSCLC.
• Analysis of mechanisms by which miRNAs modulate oncogenic pathways.
• Examination of miRNA roles in acquired and intrinsic drug resistance.
• Discussion of therapeutic strategies involving miRNA mimics or inhibitors.

Main Results:

• Certain miRNAs can up-regulate or down-regulate key oncogenic driver pathways in NSCLC.
• miRNAs play a significant role in both intrinsic and acquired resistance to targeted therapies.
• Evidence suggests miRNAs can be targeted for therapeutic intervention in NSCLC.

Conclusions:

• miRNAs are critical regulators of oncogenic pathways and drug resistance in NSCLC.
• Targeting miRNAs offers a promising strategy to overcome resistance and improve outcomes in NSCLC treatment.
• Further research into miRNA-based therapies is warranted for clinical application.